Khanna PP, Khanna D, Cutter G, et al. - This study was undertaken to evaluate whether mycophenolate mofetil (MMF) prolongs the efficacy of pegloticase. Individuals were assigned randomly in a 3:1 ratio to receive 1,000 mg MMF twice daily or placebo for 14 weeks, starting 2 weeks before receiving pegloticase and continuing while receiving intravenous pegloticase 8 mg biweekly for 12 weeks. In this study, a sum of 32 participants received ≥ 1 dose of pegloticase. This study’s findings demonstrate that MMF therapy with pegloticase is well tolerated and indicates a clinically meaningful improvement in targeted serum urate level of ≤ 6 mg/dl at 12 and 24 weeks. This research implies an innovative approach to pegloticase therapy in gout.